

ES0

FILE 'HCAPLUS' ENTERED AT 11:38:00 ON 14 AUG 2007

L1 3011 S GALACTOMANNAN  
L2 10748 S GUAR  
L3 817398 S CANCER OR TUMOR OR NEOPLAS? OR FLUOROURACIL OR FLUOROPYRIMIDI  
L4 72 S L1 AND L3  
L5 169 S L2 AND L3  
L6 15 S L1 AND L2 AND L3  
L7 40 S L4 AND (PY<2004 OR AY<2004 OR PRY<2004)  
L8 112 S L5 AND (PY<2004 OR AY<2004 OR PRY<2004)  
L9 12 S L6 AND (PY<2004 OR AY<2004 OR PRY<2004)  
L10 53680 S INTERLEUKIN(W) (2 OR 12)  
L11 4527 S ALPHA-INTERFERON  
L12 4 S L1 AND L10  
L13 7 S L2 AND L10

FILE 'STNGUIDE' ENTERED AT 12:47:04 ON 14 AUG 2007

FILE 'HCAPLUS' ENTERED AT 12:48:06 ON 14 AUG 2007

L14 4 S L12 AND (PY<2004 OR AY<2004 OR PRY<2004)  
L15 5 S L13 AND (PY<2004 OR AY<2004 OR PRY<2004)  
L16 2 S L14 AND L15

=> file hcaplus		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	0.63	0.63

FILE 'HCAPLUS' ENTERED AT 11:38:00 ON 14 AUG 2007  
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
 COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 14 Aug 2007 VOL 147 ISS 8  
 FILE LAST UPDATED: 13 Aug 2007 (20070813/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s galactomannan

L1 3011 GALACTOMANNAN

=> s guar

L2 10748 GUAR

=> s cancer or tumor or neoplas? or fluorouracil or fluoropyrimidine or fluorodeoxyuridine or chemotherap?

325472 CANCER  
 417600 TUMOR  
 505396 NEOPLAS?  
 19840 FLUOROURACIL  
 1278 FLUOROPYRIMIDINE  
 1906 FLUORODEOXYURIDINE  
 94250 CHEMOTHERAP?

L3 817398 CANCER OR TUMOR OR NEOPLAS? OR FLUOROURACIL OR FLUOROPYRIMIDINE OR FLUORODEOXYURIDINE OR CHEMOTHERAP?

=> s l1 and l3

L4 72 L1 AND L3

=> s l2 and l3

L5 169 L2 AND L3

=> s l1 and l2 and l3

L6 15 L1 AND L2 AND L3

=> s l4 and (PY<2004 or AY<2004 or PRY<2004)

23927690 PY<2004  
4731693 AY<2004  
4213609 PRY<2004  
L7 40 L4 AND (PY<2004 OR AY<2004 OR PRY<2004)

=> s 15 and (PY<2004 or AY<2004 or PRY<2004)

23927690 PY<2004  
4731693 AY<2004  
4213609 PRY<2004  
L8 112 L5 AND (PY<2004 OR AY<2004 OR PRY<2004)

=> s 16 and (PY<2004 or AY<2004 or PRY<2004)

23927690 PY<2004  
4731693 AY<2004  
4213609 PRY<2004  
L9 12 L6 AND (PY<2004 OR AY<2004 OR PRY<2004)

=> flie stnguide

FLIE IS NOT A RECOGNIZED COMMAND

The previous command name entered was not recognized by the system.

For a list of commands available to you in the current file, enter

"HELP COMMANDS" at an arrow prompt (=>).

=> d 19 1-12 ti abs bib

L9 ANSWER 1 OF 12 HCAPLUS COPYRIGHT 2007 ACS on STN  
TI Use of isomalt (mixture of 1,6-GPS and 1,1-GPM) as a prebiotic for the  
production of food and feed additives and medicaments used for the  
treatment of intestinal diseases, among other things  
AB The invention relates to a novel use of a mixture of 6-O- $\alpha$ -D-  
glucopyranosyl-D-sorbitol (1,6-GPS) and 1-O- $\alpha$ -D-glucopyranosyl-D-  
mannitol (1,1-GPM) as a bifidogenic prebiotic optionally containing a  
probiotic, to be used as or for producing a food item, semi-luxury food,  
fodder, or a medicament. Said medicament is used for the treatment and/or  
prevention of intestinal diseases such as chronic inflammatory intestinal  
diseases, intestinal cancer, bacterial intestinal infections,  
among other things.  
AN 2004:1154570 HCAPLUS <<LOGINID::20070814>>  
DN 142:73725  
TI Use of isomalt (mixture of 1,6-GPS and 1,1-GPM) as a prebiotic for the  
production of food and feed additives and medicaments used for the  
treatment of intestinal diseases, among other things  
IN Klingeberg, Michael; Kozianowski, Gunhild; Kunz, Markwart; Theis, Stephan  
PA Suedzucker Aktiengesellschaft Mannheim/ochsenfurt, Germany  
SO PCT Int. Appl., 55 pp.  
CODEN: PIXXD2  
DT Patent  
LA German  
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004112505	A1	20041229	WO 2004-EP6030	20040604 <--
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,			

SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,  
SN, TD, TG

DE 10328180	A1	20050113	DE 2003-10328180	20030616 <--
AU 2004248895	A1	20041229	AU 2004-248895	20040604 <--
CA 2527765	A1	20041229	CA 2004-2527765	20040604 <--
EP 1641354	A1	20060405	EP 2004-739586	20040604 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
CN 1802101	A	20060712	CN 2004-80016063	20040604 <--
BR 2004011528	A	20060801	BR 2004-11528	20040604 <--
JP 2006527586	T	20061207	JP 2006-515829	20040604 <--
MX 2005PA13815	A	20060313	MX 2005-PA13815	20051216 <--
NO 2006000185	A	20060315	NO 2006-185	20060111 <--
US 2006147500	A1	20060706	US 2006-561122	20060202 <--
PRAI DE 2003-10328180	A	20030616 <--		
WO 2004-EP6030	W	20040604		

RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 2 OF 12 HCAPLUS COPYRIGHT 2007 ACS on STN

TI Improved thickened beverages for dysphagia

AB The present invention relates to thickened beverage compns. More particularly the invention relates to beverage compns. thickened for the management of dysphagia. More particularly this invention relates to the production of thickened beverages by a dispensing machine that is also capable of dispensing non-thickened beverages. The thickened beverages containing soluble food fiber thickener, especially xanthan gum, allows patients with swallowing difficulty to successfully swallow the beverages.

AN 2004:681524 HCAPLUS <<LOGINID::20070814>>

DN 141:195323

TI Improved thickened beverages for dysphagia

IN Holahan, John L.

PA Simply Thick LLC, USA

SO PCT Int. Appl., 36 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004069179	A2	20040819	WO 2004-US2795	20040131 <--
	WO 2004069179	A3	20050714		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI				
	RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2004209974	A1	20040819	AU 2004-209974	20040131 <--
	CA 2509715	A1	20040819	CA 2004-2509715	20040131 <--
	EP 1590004	A2	20051102	EP 2004-707165	20040131 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	JP 2006516995	T	20060713	JP 2006-503223	20040131 <--
	US 2006051296	A1	20060309	US 2005-542506	20050715 <--
PRAI	US 2003-443941P	P	20030131 <--		
	US 2003-444079P	P	20030131 <--		
	US 2003-444080P	P	20030131 <--		
	US 2003-444082P	P	20030131 <--		
	WO 2004-US2795	W	20040131		

L9 ANSWER 3 OF 12 HCAPLUS COPYRIGHT 2007 ACS on STN

TI Coating technique for deposition of drug substance on a substrate  
 AB The present invention relates to a multi-layered, physiol. tolerated oral dosage form for pharmaceuticals. The dosage form comprises a central core, a middle layer, and an outer shell, at least one of which includes at least one pharmaceutical. By varying the diameter of the core, a different middle layer volume is obtained within a fixed outer shell dimension. This gives the ability to obtain different dosage strengths for one composition without the need of reformulation work. The oral dosage form is produced in a single-step, continuous process by coating the core with the middle layer and the outer shell. Tablets were prepared containing a core, an overlay, and a shell. The overlay and the shell were PEG-200 and Eudragit E100, resp. The core was a strand of poly(vinylidene fluoride).

AN 2003:851103 HCAPLUS <<LOGINID::20070814>>

DN 139:341755

TI Coating technique for deposition of drug substance on a substrate

IN Verreck, Geert; Rosenblatt, Joel; Liland, Alfred

PA Ethicon, Inc., USA

SO Eur. Pat. Appl., 12 pp.

CODEN: EPXXDW

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 1356808	A2	20031029	EP 2003-252647	20030425 <--
	EP 1356808	A3	20031112		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	US 2003203027	A1	20031030	US 2002-134305	20020426 <--
	JP 2004035547	A	20040205	JP 2003-122484	20030425 <--
	US 2005158385	A1	20050721	US 2005-77680	20050311 <--
PRAI	US 2002-134305	A	20020426	<--	

L9 ANSWER 4 OF 12 HCAPLUS COPYRIGHT 2007 ACS on STN

TI Malleable protein matrix and uses thereof

AB The present invention relates to a malleable protein matrix (MPM) which is the reaction product of the agglomeration of proteins after a fermentation process, exhibits biol. activities and is suitable for the incorporation (or encapsulation) of various hydrophilic or lipophilic substances. The present invention also relates to the process for the preparation of the malleable protein matrix and its uses in food, drug, medical and cosmetic products.

AN 2003:511049 HCAPLUS <<LOGINID::20070814>>

DN 139:84363

TI Malleable protein matrix and uses thereof

IN Simard, Eric; Pilote, Dominique; Dupont, Claude; Lajoie, Nathalie; Paquet, Marcel; Lemieux, Pierre; Goyette, Philippe

PA Technologies Biolactis Inc., Can.

SO PCT Int. Appl., 92 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003053158	A2	20030703	WO 2002-CA1988	20021220 <--
	WO 2003053158	A3	20030828		
	WO 2003053158	A9	20040408		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

CA 2470776 A1 20030703 CA 2002-2470776 20021220 <--  
 AU 2002351606 A1 20030709 AU 2002-351606 20021220 <--  
 EP 1458247 A2 20040922 EP 2002-787279 20021220 <--  
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK  
 JP 2005513076 T 20050512 JP 2003-553926 20021220 <--  
 US 2006057131 A1 20060316 US 2005-499313 20050224 <--  
 PRAI US 2001-341232P P 20011220 <--  
 WO 2002-CA1988 W 20021220 <--

L9 ANSWER 5 OF 12 HCAPLUS COPYRIGHT 2007 ACS on STN

TI Polymer-based matrixes for wound dressing devices containing antimicrobial agents

AB The present invention comprises methods and compns. for treating wounds. More particularly, the present invention comprises methods and compns. for wound dressing devices comprising a matrix comprising a polymer network and a non-gellable polysaccharide having active agents, such as wound healing agents, incorporated therein. The matrix may be formed into any desired shape for the treatment of wounds. The incorporation of the antimicrobial agent, penicillin G, into the matrix was evaluated by dissolving 1+106 units of penicillin G powder into 50 mL water. Acrylamide, methylenebisacrylamide, glycerol, and a guar gum/isopropyl alc. mixture were mixed for 2 h. The penicillin solution was then added to an aqueous solution of TEMED and after thorough mixing, ammonium persulfate in water was added and mixed thoroughly. The mixture was then poured into sheet molds and allowed to gel. The sheets of semi-solid gel material were stripped from the mold and dehydrated to approx. 7% their original water content for storage. Prior to testing, the sheets were placed in a humidified environment until the sheet weight had increased to approx. 118-122% the storage weight. Disks were cut and placed onto the surfaces of agar plates that had previously been seeded with various strains of microorganisms (Staphylococcus aureus; Escherichia coli; Candida albicans; Pseudomonas aeruginosa). Zones of inhibition were measured around the penicillin containing matrix but not the control matrix on the S. aureus, E. coli, and P. aeruginosa plates. The results demonstrated the release of active penicillin G after its incorporation into the matrix.

AN 2002:182217 HCAPLUS <<LOGINID::20070814>>

DN 136:236843

TI Polymer-based matrixes for wound dressing devices containing antimicrobial agents

IN Gibbins, Bruce L.

PA AcryMed, Inc., USA

SO U.S., 14 pp., Cont.-in-part of U.S. 5,928,174.

CODEN: USXXAM

DT Patent

LA English

FAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 6355858	B1	20020312	US 1998-191223	19981113 <--
	US 6605751	B1	20030812	US 2000-675892	20000929 <--
	US 2004010215	A1	20040115	US 2003-441275	20030519 <--
	US 6897349	B2	20050524		
	US 2005226931	A1	20051013	US 2004-978556	20041101 <--
PRAI	US 1997-971074	A2	19971114	<--	
	US 1998-191223	A2	19981113	<--	
	US 1999-157000P	P	19991001	<--	
	US 2000-212455P	P	20000619	<--	
	US 2000-675892	A1	20000929	<--	

US 2003-441275 A1 20030519 <--  
RE.CNT 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 6 OF 12 HCAPLUS COPYRIGHT 2007 ACS on STN  
TI Galactomannan Oligosaccharide and procedure for their production  
as well as their use  
AB A process is provided for the manufacture of galactomannan derived  
oligosaccharides which can hinder infectious diseases, colon  
cancer, osteoporosis and stimulate the immune system. Thus,  
Bacillus subtilis cells immobilized in calcium alginate were employed to  
hydrolyze guar gum forming oligosaccharides with a d.p. less  
than 15 residues preferably between 2 and 7 residues. The resulting  
oligosaccharides were partially purified by ion exchange chromatog.  
AN 2001:449805 HCAPLUS <<LOGINID::20070814>>  
DN 135:45276  
TI Galactomannan Oligosaccharide and procedure for their production  
as well as their use  
IN Klingeberg, Michael; Kunz, Markwart; Ludwig, Eva; Munir, Mohammad; Rittig,  
Frank; Vogel, Manfred  
PA Suedzucker Aktiengesellschaft Mannheim/Ochsenfurt, Germany  
SO Ger. Offen., 12 pp.  
CODEN: GWXXBX  
DT Patent  
LA German  
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	---	-----	-----	-----
PI	DE 19961182	A1	20010621	DE 1999-19961182	19991218 <--
	DE 19961182	B4	20060112		
	CA 2394640	A1	20010621	CA 2000-2394640	20001212 <--
	WO 2001044489	A2	20010621	WO 2000-EP12574	20001212 <--
	WO 2001044489	A3	20020214		
	W: AU, CA, IL, JP, KR, MX, RU, US				
	RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL,				
	PT, SE, TR				
	EP 1303632	A2	20030423	EP 2000-991171	20001212 <--
	EP 1303632	B1	20041006		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				
	IE, FI, CY, TR				
	JP 2003516757	T	20030520	JP 2001-545566	20001212 <--
	AT 278799	T	20041015	AT 2000-991171	20001212 <--
	AU 779681	B2	20050203	AU 2001-31575	20001212 <--
	PT 1303632	T	20050228	PT 2000-991171	20001212 <--
	ES 2228661	T3	20050416	ES 2000-991171	20001212 <--
	RU 2281331	C2	20060810	RU 2002-119059	20001212 <--
	MX 2002PA06044	A	20030128	MX 2002-PA6044	20020618 <--
	US 2003162300	A1	20030828	US 2002-168044	20021219 <--
PRAI	DE 1999-19961182	A	19991218	<--	
	WO 2000-EP12574	W	20001212	<--	

RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 7 OF 12 HCAPLUS COPYRIGHT 2007 ACS on STN  
TI Nutritional compositions which contain slightly negatively charged,  
non-digestible polysaccharides and the use thereof for reducing transport  
through tight junctions  
AB The present invention relates to a nutritional composition which contains  
slightly neg. charged non-digestible polysaccharides having a mol. weight of  
8 kD to 40,000 kD, characterized in that the rise in the viscosity of the  
composition caused by the polysaccharides is less than 20 mPa.s. The invention  
also relates to the use of this nutritional composition to reduce the uptake of  
high mol. weight substances, allergens and microorganisms through the  
intestinal wall, more particularly to reduce transport of high mol. weight

substances, allergens and microorganisms through the tight junctions in the intestines. The nutritional compns. can be used to prevent or to treat allergies, allergic reactions, sepsis and inflammatory processes, such as those which can arise under emotional and phys. stress, ischemia, reperfusion damage during and after operations, following radiation treatment and/or chemotherapy of cancer patients and in the case of inflammatory intestinal diseases, diarrhea and allergies.

AN 2000:706937 HCAPLUS <<LOGINID::20070814>>

DN 133:265962

TI Nutritional compositions which contain slightly negatively charged, non-digestible polysaccharides and the use thereof for reducing transport through tight junctions

IN Bijlsma, Pieter Brandt; Groot, Jacques Alphons; Timmermans, Johannes Wilhelmus; Van Der Meulen, Jan; Kiliaan, Amanda Johanne

PA N.V. Nutricia, Neth.

SO PCT Int. Appl., 20 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000057727	A1	20001005	WO 2000-NL187	20000321 <--
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	NL 1011680	C2	20000927	NL 1999-1011680	19990326 <--
	EP 1164874	A1	20020102	EP 2000-914366	20000321 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	JP 2002539809	T	20021126	JP 2000-607492	20000321 <--
	US 6686341	B1	20040203	US 2002-937395	20020102 <--
PRAI	NL 1999-1011680	A	19990326 <--		
	WO 2000-NL187	W	20000321 <--		

RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 8 OF 12 HCAPLUS COPYRIGHT 2007 ACS on STN

TI Immunoglobulin production regulating activity of dietary fibers

AB In rats fed some types of dietary fat, class specific increases or decreases of serum Igs (Ig), changes in Ig productivity of spleen and mesenteric lymph node (MLN) lymphocytes, changes in T cell populations of splenocytes, and changes in cytokine productivity in MLN lymphocytes have been reported. In comparison with the water-insol. dietary fiber cellulose the soluble forms pectin, glucomannan and chitosan enhanced the production of IgA and IgG, but inhibit the production of IgE. The proportion

of

CD8 cells in rats fed these dietary fibers are significantly lower than rats fed cellulose and the proportion of CD4 cells is significantly elevated. In addition, production of interferon- $\gamma$  and tissue necrosis factor- $\alpha$  by MLN lymphocytes is significantly enhanced by pectin as compared with cellulose. These results suggest that dietary fibers in the diet affect Ig production by influencing T cell differentiation and cytokine synthesis. Though similar Ig production regulating activity is observed galactomannan guar gum, enzymically degraded guar gum exerts lower activity. When MLN lymphocytes are cultured in the presence of glucomannan, galactomannan, or their structural sugars, no change in the Ig productivity has been observed These results suggest that the above effects are not due to the direct

interaction of dietary fibers or their metabolites on the Ig production system.

AN 2000:418862 HCAPLUS <<LOGINID::20070814>>  
DN 133:281020  
TI Immunoglobulin production regulating activity of dietary fibers  
AU Yamada, Koji  
CS Lab. Food Chem., Div. Bioresource Bioenvironmental Sci., Grad. Sch. Kyushu Univ., Fukuoka, 812-8581, Japan  
SO Foods & Food Ingredients Journal of Japan (2000), 186, 26-32  
CODEN: FFIJER; ISSN: 0919-9772  
PB FFI Janaru  
DT Journal  
LA Japanese

L9 ANSWER 9 OF 12 HCAPLUS COPYRIGHT 2007 ACS on STN  
TI Composition and pharmaceutical dosage form for colonic drug delivery using polysaccharides  
AB A colonic drug delivery composition contains a first polysaccharide and a second polysaccharide wherein both polysaccharides are degradable by colonic enzymes and are mixed at a environmental pH of about 7 or above. A colon selective pharmaceutical composition and dosage form for oral delivery of a drug, nutrient, diagnostic reagent, or mixture thereof includes the drug, nutrient, diagnostic reagent, or mixture thereof in contact with the polysaccharide composition. A method of preparing such a colonic drug delivery composition and the colon selective pharmaceutical composition and dosage form

are

also disclosed. Capsules filled with budesonide pellets were coated with a composition containing pectin and guar gum at the ratio of 4 to 1 (pH 8), to a thickness of 15 mg/cm<sup>2</sup>. The capsules were disintegrated in 60 min in simulated colonic fluid, but not disintegrated in simulated gastric or intestinal fluid during 24 h studies.

AN 2000:68148 HCAPLUS <<LOGINID::20070814>>  
DN 132:113102  
TI Composition and pharmaceutical dosage form for colonic drug delivery using polysaccharides  
IN Lee, Seung Seo; Lim, Chang Baeg; Pai, Chaul Min; Lee, Sujung; Park, In; Seo, Moon Gun; Park, Heenam  
PA Samyang Corporation, S. Korea  
SO Eur. Pat. Appl., 13 pp.  
CODEN: EPXXDW  
DT Patent  
LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	EP 974344	A2	20000126	EP 1999-305600	19990715 <--
	EP 974344	A3	20000301		
	EP 974344	B1	20040303		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	KR 2000011247	A	20000225	KR 1999-14665	19990423 <--
	CA 2336815	A1	20000203	CA 1999-2336815	19990520 <--
	CA 2336815	C	20050607		
	WO 2000004924	A1	20000203	WO 1999-KR250	19990520 <--
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	AU 9940627	A	20000214	AU 1999-40627	19990520 <--
	AU 744183	B2	20020214		
	JP 2002521346	T	20020716	JP 2000-560917	19990520 <--

	US 6413494	B1	20020702	US 1999-318579	19990525 <--
	AT 260649	T	20040315	AT 1999-305600	19990715 <--
	ES 2214813	T3	20040916	ES 1999-305600	19990715 <--
	KR 2001074641	A	20010804	KR 2001-700082	20010104 <--
	MX 2001PA00768	A	20020408	MX 2001-PA768	20010122 <--
PRAI	KR 1998-29740	A	19980723	<--	
	KR 1999-14665	A	19990423	<--	
	WO 1999-KR250	W	19990520	<--	

L9 ANSWER 10 OF 12 HCAPLUS COPYRIGHT 2007 ACS on STN

TI Improved wound dressing device and methods

AB The present invention comprises methods and compns. for treating wounds. More particularly, the present invention comprises methods and compns. for wound dressing devices comprising a matrix comprising a polymer network and a non-gellable polysaccharide having active agents, such as wound healing agents, incorporated therein. The matrix may be formed into any desired shape for treatment of wounds. A mixing tank was charged with 161.4 kg water and 9.1894 kg acrylamide, and 0.10347 kg of methylenebisacrylamide and 9.3046 kg glycerol were added and mixed. Then, 1.0213 kg guar gum was dispersed in a mixture containing 0.9770 kg isopropanol and 2 kg water. The solution of guar gum was dispersed into the acrylamide mixture. After suitable mixing, 0.1042 kg TEMED was added and polymerization was catalyzed with 0.0999 kg ammonium persulfate.

While the batch was still liquid, it was poured into molds to form sheets. After gelling had occurred, sheets were transferred to a desiccator and dehydrated to form a stable sheet.

AN 1999:350613 HCAPLUS <<LOGINID::20070814>>

DN 130:357215

TI Improved wound dressing device and methods

IN Gibbins, Bruce L.

PA USA

SO PCT Int. Appl., 32 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
PI	WO 9925395	A2	19990527	WO 1998-US24272	19981113 <--	
	WO 9925395	A3	19990812			
	W:			AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW		
	RW:			GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG		
	AU 9916991	A	19990607	AU 1999-16991	19981113 <--	
	EP 1030695	A2	20000830	EP 1998-961733	19981113 <--	
	EP 1030695	B1	20050406			
	R:			AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI		
	AT 292481	T	20050415	AT 1998-961733	19981113 <--	
PRAI	US 1997-971074	A2	19971114	<--		
	WO 1998-US24272	W	19981113	<--		

L9 ANSWER 11 OF 12 HCAPLUS COPYRIGHT 2007 ACS on STN

TI  $\beta$ -Glucuronidase-inhibiting compositions containing low-molecular weight galactomannan

AB The title compns., useful for prevention of colon cancer, contain low-mol. weight galactomannan,  $\geq 80\%$  of which is linear chains of 30-200 mannose units. A drink containing low-mol.-weight

galactomannan (manufactured from guar gum with  $\beta$ -mannase) was ingested by volunteers to show less formation of  $\beta$ -glucuronidase by intestinal bacteria.

AN 1995:235235 HCAPLUS <<LOGINID::20070814>>

DN 122:8814

TI  $\beta$ -Glucuronidase-inhibiting compositions containing low-molecular weight galactomannan

IN Ishihara, Noryuki; Ookubo, Tsutomu

PA Taiyo Kagaku Kk, Japan

SO Jpn. Kokai Tokkyo Koho, 4 pp.

CODEN: JKXXAF

DT Patent

LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 06256196	A	19940913	JP 1993-67497	19930302 <--
	JP 3801658	B2	20060726		
PRAI	JP 1993-67497		19930302	<--	

L9 ANSWER 12 OF 12 HCAPLUS COPYRIGHT 2007 ACS on STN

TI Solid pharmaceutical compositions for oral administration with prolonged gastric residence

AB The title compns. comprise an active ingredient characterized by erratic gastrointestinal absorption, a high d. inorg. substance, such as BaSO<sub>4</sub>, Fe, Mg trisilicate, and a bioadhesive polymer, such as cellulose ethers and acrylate copolymers. For example, a tablet was formulated containing nifedipine with micronized crosslinked PVP (1:5) 240, BaSO<sub>4</sub> 235, Methocel A4C 155, Aerosil 200 5, xanthan gum 30, galactomannan 30, and Mg stearate 5 mg.

AN 1993:154582 HCAPLUS <<LOGINID::20070814>>

DN 118:154582

TI Solid pharmaceutical compositions for oral administration with prolonged gastric residence

IN Esposito, Pierandrea; Carli, Fabio

PA Vectorpharma International S.p.A., Italy

SO Eur. Pat. Appl., 20 pp.

CODEN: EPXXDW

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 526862	A1	19930210	EP 1992-113187	19920803 <--
	EP 526862	B1	19960214		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
	AT 134134	T	19960215	AT 1992-113187	19920803 <--
	ES 2086029	T3	19960616	ES 1992-113187	19920803 <--
PRAI	IT 1991-MI2212	A	19910806	<--	

=> d his

(FILE 'HOME' ENTERED AT 11:36:11 ON 14 AUG 2007)

FILE 'HCAPLUS' ENTERED AT 11:38:00 ON 14 AUG 2007

L1 3011 S GALACTOMANNAN  
 L2 10748 S GUAR  
 L3 817398 S CANCER OR TUMOR OR NEOPLAS? OR FLUOROURACIL OR FLUOROPYRIMIDI  
 L4 72 S L1 AND L3  
 L5 169 S L2 AND L3  
 L6 15 S L1 AND L2 AND L3  
 L7 40 S L4 AND (PY<2004 OR AY<2004 OR PRY<2004)  
 L8 112 S L5 AND (PY<2004 OR AY<2004 OR PRY<2004)

L9 12 S L6 AND (PY<2004 OR AY<2004 OR PRY<2004)

=> log hold

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	36.56	37.19
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-9.36	-9.36

SESSION WILL BE HELD FOR 120 MINUTES  
STN INTERNATIONAL SESSION SUSPENDED AT 11:38:42 ON 14 AUG 2007

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTAEXO1623

PASSWORD:

\* \* \* \* \* RECONNECTED TO STN INTERNATIONAL \* \* \* \* \*  
SESSION RESUMED IN FILE 'HCAPLUS' AT 12:45:33 ON 14 AUG 2007  
FILE 'HCAPLUS' ENTERED AT 12:45:33 ON 14 AUG 2007  
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	36.56	37.19
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-9.36	-9.36

=> s interleukin(w) (2 or 12)

163794 INTERLEUKIN  
9254807 2  
1485332 12

L10 53680 INTERLEUKIN(W) (2 OR 12)

=> s alpha-interferon

1703981 ALPHA  
78349 INTERFERON

L11 4527 ALPHA-INTERFERON  
(ALPHA(W) INTERFERON)

=> s l1 and l10

L12 4 L1 AND L10

=> s l2 and l10

L13 7 L2 AND L10

=> file stnguide

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	44.36	44.99

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
CA SUBSCRIBER PRICE	ENTRY	SESSION
	-9.36	-9.36

FILE 'STNGUIDE' ENTERED AT 12:47:04 ON 14 AUG 2007  
 USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT  
 COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

FILE CONTAINS CURRENT INFORMATION.  
 LAST RELOADED: Aug 10, 2007 (20070810/UP).

=> file hcaplus  
 COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
0.12	45.11

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
CA SUBSCRIBER PRICE	ENTRY	SESSION
	0.00	-9.36

FILE 'HCAPLUS' ENTERED AT 12:48:06 ON 14 AUG 2007  
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
 COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 14 Aug 2007 VOL 147 ISS 8  
 FILE LAST UPDATED: 13 Aug 2007 (20070813/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> S L12 AND (PY<2004 OR AY<2004 OR PRY<2004)

23927690 PY<2004  
 4731693 AY<2004  
 4213609 PRY<2004

L14 4 L12 AND (PY<2004 OR AY<2004 OR PRY<2004)

=> S L13 AND (PY<2004 OR AY<2004 OR PRY<2004)

23927690 PY<2004  
 4731693 AY<2004  
 4213609 PRY<2004

L15 5 L13 AND (PY<2004 OR AY<2004 OR PRY<2004)

=> s l14 and l15

L16 2 L14 AND L15

=> file stnguide

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	2.60	47.71
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-9.36

FILE 'STNGUIDE' ENTERED AT 12:48:13 ON 14 AUG 2007  
 USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT  
 COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

FILE CONTAINS CURRENT INFORMATION.  
 LAST RELOADED: Aug 10, 2007 (20070810/UP).

=> d l16 1-2 ti abs bib  
 YOU HAVE REQUESTED DATA FROM FILE 'HCAPLUS' - CONTINUE? (Y)/N:y

L16 ANSWER 1 OF 2 HCAPLUS COPYRIGHT 2007 ACS on STN  
 TI Autologous ghrelin and encoding nucleic acid and foreign T cell epitope  
 conjugates for vaccination against obesity and excess body fat increase or  
 loss in human and animal  
 AB Disclosed are novel methods that generally rely on immunization against  
 autologous ghrelin. Immunization is preferably effected by administration  
 of analogs of autologous ghrelin, said analogs being capable of inducing  
 antibody production against the autologous ghrelin polypeptides. Especially  
 preferred as an immunogen is autologous ghrelin, which has been modified  
 by introduction of one single or a few foreign, immunodominant and  
 promiscuous T-cell epitopes. Also disclosed are nucleic acid vaccination  
 against ghrelin and vaccination using live vaccines as well as methods and  
 means useful for the vaccination. Such methods and means include methods  
 for the preparation of analogs and pharmaceutical formulations, as well as  
 nucleic acid fragments, vectors, transformed cells, polypeptides and  
 pharmaceutical formulations.  
 AN 2004:252369 HCAPLUS <<LOGINID::20070814>>  
 DN 140:269531  
 TI Autologous ghrelin and encoding nucleic acid and foreign T cell epitope  
 conjugates for vaccination against obesity and excess body fat increase or  
 loss in human and animal  
 IN Boving, Tine Elisabeth Gottschalk; Klysner, Steen  
 PA Pharmexa A/s, Den.  
 SO PCT Int. Appl., 83 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004024183	A1	20040325	WO 2003-DK592	20030912 <--
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,				
	CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE,				
	GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK,				
	LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ,				
	OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,				
	TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,				
	KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,				
	FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,				
	BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2498739	A1	20040325	CA 2003-2498739	20030912 <--
	AU 2003263150	A1	20040430	AU 2003-263150	20030912 <--
	EP 1539232	A1	20050615	EP 2003-794825	20030912 <--

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK

CN 1694724	A	20051109	CN 2003-825086	20030912 <--
JP 2006504413	T	20060209	JP 2004-535024	20030912 <--
MX 2005PA02699	A	20050920	MX 2005-PA2699	20050310 <--
IN 2005KN00485	A	20060623	IN 2005-KN485	20050323 <--
NO 2005001779	A	20050411	NO 2005-1779	20050411 <--
ZA 2005002929	A	20060222	ZA 2005-2929	20050411 <--
PRAI DK 2002-1345	A	20020912	<--	
US 2002-410164P	P	20020912	<--	
WO 2003-DK592	W	20030912	<--	

RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 2 OF 2 HCAPLUS COPYRIGHT 2007 ACS on STN  
 TI Silver-containing compositions, devices and methods for making them  
 AB The present invention comprises methods and compns. for making a  
 silver-containing antimicrobial hydrophilic material. More particularly, the  
 present invention comprises methods and compns. for stabilized silver  
 antimicrobial devices comprising a matrix comprising a polymer network and  
 a non-gelable polysaccharide, and an active agent. The matrix may be  
 formed into any desired shape for its desired uses.  
 AN 2001:265285 HCAPLUS <<LOGINID::20070814>>  
 DN 134:300843  
 TI Silver-containing compositions, devices and methods for making them  
 IN Gibbins, Bruce L.; Hopman, Lance D.  
 PA Acrymed, USA  
 SO PCT Int. Appl., 63 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	---	-----	-----	-----
PI	WO 2001024839	A1	20010412	WO 2000-US26890	20000929 <--
	WO 2001024839	A9	20021114		
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,				
	CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,				
	HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT,				
	LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU,				
	SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN,				
	YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,				
	DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ,				
	CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP	1216065	A1	20020626	EP 2000-970522	20000929 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				
	IE, SI, LT, LV, FI, RO, MK, CY, AL				
PRAI US	1999-157000P	P	19991001	<--	
	US 2000-212455P	P	20000619	<--	
	WO 2000-US26890	W	20000929	<--	

RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d l15 1-5 ti  
 YOU HAVE REQUESTED DATA FROM FILE 'HCAPLUS' - CONTINUE? (Y)/N:y

L15 ANSWER 1 OF 5 HCAPLUS COPYRIGHT 2007 ACS on STN  
 TI Nonsteroidal immunomodulating kit and composition and uses thereof

L15 ANSWER 2 OF 5 HCAPLUS COPYRIGHT 2007 ACS on STN

TI Autologous ghrelin and encoding nucleic acid and foreign T cell epitope conjugates for vaccination against obesity and excess body fat increase or loss in human and animal

L15 ANSWER 3 OF 5 HCAPLUS COPYRIGHT 2007 ACS on STN

TI Nanoparticulate compositions of angiogenesis inhibitors

L15 ANSWER 4 OF 5 HCAPLUS COPYRIGHT 2007 ACS on STN

TI Silver-containing compositions, devices and methods for making them

L15 ANSWER 5 OF 5 HCAPLUS COPYRIGHT 2007 ACS on STN

TI Gas and gaseous precursor filled microspheres as topical and subcutaneous delivery vehicles

=> d l15 1 3 5 ti abs bib

YOU HAVE REQUESTED DATA FROM FILE 'HCAPLUS' - CONTINUE? (Y)/N:y

L15 ANSWER 1 OF 5 HCAPLUS COPYRIGHT 2007 ACS on STN

TI Nonsteroidal immunomodulating kit and composition and uses thereof

AB A composition and therapeutic kit including an aerosol packaging assembly including a container accommodating a pressurized product and an outlet capable of releasing a foamable composition, including a nonsteroidal immunomodulating agent as a foam. The pressurized product includes a foamable composition including: a) a container accommodating a pressurized product; and b) an outlet capable of releasing the pressurized product as a foam; wherein the pressurized product comprises a foamable composition including: i. a nonsteroidal immunomodulating agent; ii. at least one organic carrier selected from the group consisting of a hydrophobic organic carrier, a polar solvent, an emollient and mixts. thereof, at a concentration of about

2\*

to about 50% by weight; iii. a surface-active agent; iv. about 0.1% to about 5% by weight of a therapeutically active foam adjuvant, selected from the group consisting of a fatty alc., a fatty acid, a hydroxy fatty acid; and mixts. thereof; v. about 0.01 % to about 5% by weight of at least one polymeric additive selected from the group consisting of a bioadhesive agent, a gelling agent, a film forming agent and a phase change agent; vi. water; and vii. liquefied or compressed gas propellant at a concentration of about 3% to about 25% by weight of the total composition

AN 2005:1132617 HCAPLUS <<LOGINID::20070814>>

DN 143:393082

TI Nonsteroidal immunomodulating kit and composition and uses thereof

IN Tamarkin, Dov; Eini, Meir; Friedman, Doron

PA Foamix Ltd., Israel

SO U.S. Pat. Appl. Publ., 18 pp., Cont.-in-part of U.S. Ser. No. 911,367.

CODEN: USXXCO

DT Patent

LA English

FAN.CNT 17

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	---	-----	-----	-----
PI	US 2005232869	A1	20051020	US 2005-78902	20050311 <--
	WO 2004037225	A2	20040506	WO 2003-IB5527	20031024 <--
	WO 2004037225	A3	20041229		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,				

FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,  
 BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG  
 US 2005069566 A1 20050331 US 2004-911367 20040804 <--  
 WO 2007007208 A2 20070118 WO 2006-IB2755 20060310  
 W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,  
 CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,  
 GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR,  
 KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX,  
 MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE,  
 SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC,  
 VN, YU, ZA, ZM, ZW  
 RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,  
 IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,  
 CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,  
 GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,  
 KG, KZ, MD, RU, TJ, TM  
 PRAI IL 2002-152486 A 20021025 <--  
 US 2002-429546P P 20021129 <--  
 US 2003-492385P P 20030804 <--  
 WO 2003-IB5527 A2 20031024 <--  
 US 2004-911367 A2 20040804  
 US 2005-78902 A 20050311

L15 ANSWER 3 OF 5 HCAPLUS COPYRIGHT 2007 ACS on STN

TI Nanoparticulate compositions of angiogenesis inhibitors

AB Nanoparticulate compns. comprising at least one poorly soluble angiogenesis inhibitor and at least one surface stabilizer are described. The nanoparticulate compns. have an average particle size of less than about 2000 nm. The invention also describes methods of making and using such compns. For example, a nanoparticulate dispersion was prepared by milling a mixture containing 5% 2-methoxyestradiol, 1% hydroxypropyl cellulose of low viscosity (HPC-SL), and 0.05% docusate sodium (DOSS). The mean particle size of the nanoparticulate dispersion of 2-methoxyestradiol was 153 nm, with 50% < 144 nm, 90% < 217 nm, and 95% < 251 nm. After 2 wk storage at 5°, the nanoparticulate dispersion of 2-methoxyestradiol had a mean particle size of 195 nm.

AN 2003:777565 HCAPLUS <<LOGINID::20070814>>

DN 139:296972

TI Nanoparticulate compositions of angiogenesis inhibitors

IN Merisko-Liversidge, Elaine; Bosch, H. William; Cary, Greta G.; Pruitt, John; Ryde, Tuula; Jain, Rajeev; Walters, Amy

PA Elan Pharma International Ltd., USA

SO PCT Int. Appl., 72 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003080027	A1	20031002	WO 2003-US8546	20030320 <--
W:				
AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,				
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,				
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,				
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM,				
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT,				
TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW:				
GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,				
KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,				
FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,				
BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2479665	A1	20031002	CA 2003-2479665	20030320 <--
AU 2003230691	A1	20031008	AU 2003-230691	20030320 <--
US 2004033267	A1	20040219	US 2003-392403	20030320 <--
EP 1490030	A1	20041229	EP 2003-723781	20030320 <--

EP 1490030 B1 20061025  
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK  
 JP 2005530712 T 20051013 JP 2003-577857 20030320 <--  
 AT 343376 T 20061115 AT 2003-723781 20030320 <--  
 EP 1800666 A1 20070627 EP 2006-22201 20030320 <--  
 R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,  
 IT, LI, LU, MC, NL, PT, RO, SE, SI, SK, TR  
 PRAI US 2002-365540P P 20020320 <--  
 US 2002-366542P P 20020325 <--  
 EP 2003-723781 A3 20030320 <--  
 WO 2003-US8546 W 20030320 <--  
 RE.CNT 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 5 OF 5 HCAPLUS COPYRIGHT 2007 ACS on STN  
 TI Gas and gaseous precursor filled microspheres as topical and subcutaneous  
 delivery vehicles  
 AB Gas and gaseous precursor filled microspheres, and foams provide novel  
 topical and s.c. delivery vehicles for various active ingredients,  
 including drugs and cosmetics. Gas and gaseous precursor filled  
 microcapsules were prepared from dipalmitoylphosphatidylcholine.  
 AN 1998:207280 HCAPLUS <<LOGINID::20070814>>  
 DN 128:275101  
 TI Gas and gaseous precursor filled microspheres as topical and subcutaneous  
 delivery vehicles  
 IN Unger, Evan C.; Matsunaga, Terry O.; Yellowhair, David  
 PA Imarx Pharmaceutical Corp., USA  
 SO U.S., 40 pp., Cont.-in-part of U.S. Ser. No. 307,305.  
 CODEN: USXXAM  
 DT Patent  
 LA English

FAN.CNT 21

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
PI	US 5733572	A	19980331	US 1994-346426	19941129	<--
	US 5088499	A	19920218	US 1990-569828	19900820	<--
	WO 9109629	A1	19910711	WO 1990-US7500	19901219	<--
	W: CA, JP					
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, NL, SE					
	JP 05502675	T	19930513	JP 1991-503276	19901219	<--
	JP 3309356	B2	20020729			
	AT 180170	T	19990615	AT 1991-902857	19901219	<--
	ES 2131051	T3	19990716	ES 1991-902857	19901219	<--
	CA 2069759	C	20070116	CA 1990-2069759	19901219	<--
	US 5228446	A	19930720	US 1991-717084	19910618	<--
	WO 9222247	A1	19921223	WO 1992-US2615	19920331	<--
	W: AU, CA, JP					
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, MC, NL, SE					
	AU 9220020	A	19930112	AU 1992-20020	19920331	<--
	AU 667471	B2	19960328			
	JP 06508364	T	19940922	JP 1993-500847	19920331	<--
	JP 3456584	B2	20031014			
	EP 616508	A1	19940928	EP 1992-912456	19920331	<--
	EP 616508	B1	20010718			
	EP 616508	B2	20040929			
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, MC, NL, SE					
	AT 203148	T	20010815	AT 1992-912456	19920331	<--
	ES 2159280	T3	20011001	ES 1992-912456	19920331	<--
	CA 2110491	C	20070724	CA 1992-2110491	19920331	<--
	US 5469854	A	19951128	US 1993-76239	19930611	<--
	US 5580575	A	19961203	US 1993-76250	19930611	<--
	US 5348016	A	19940920	US 1993-88268	19930707	<--
	US 5542935	A	19960806	US 1993-160232	19931130	<--

US 5585112	A	19961217	US 1993-159687	19931130 <--
US 5769080	A	19980623	US 1994-199462	19940222 <--
WO 9428874	A1	19941222	WO 1994-US5633	19940519 <--
W: AU, CA, CN, JP				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
US 5773024	A	19980630	US 1994-307305	19940916 <--
CA 2177713	A1	19950608	CA 1994-2177713	19941130 <--
WO 9515118	A1	19950608	WO 1994-US13817	19941130 <--
W: AU, CA, CN, JP				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
EP 740528	A1	19961106	EP 1995-908414	19941130 <--
EP 740528	B1	20030326		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
JP 09506098	T	19970617	JP 1995-515763	19941130 <--
AT 235228	T	20030415	AT 1995-908414	19941130 <--
US 5571497	A	19961105	US 1995-468056	19950606 <--
CN 1180310	A	19980429	CN 1996-193069	19960327 <--
CN 1102045	B	20030226		
US 6001335	A	19991214	US 1996-665719	19960618 <--
US 5935553	A	19990810	US 1996-758179	19961125 <--
US 6743779	B1	20040601	US 1997-841169	19970429 <--
US 5985246	A	19991116	US 1997-888426	19970708 <--
AU 9856271	A	19980507	AU 1998-56271	19980224 <--
AU 713127	B2	19991125		
AU 9888405	A	19981203	AU 1998-88405	19981012 <--
AU 731072	B2	20010322		
HK 1013625	A1	20000420	HK 1998-114978	19981223 <--
AU 9910043	A	19990304	AU 1999-10043	19990104 <--
GR 3036877	T3	20020131	GR 2001-401740	20011011 <--
PRAI US 1989-455707	B2	19891222	<--	
US 1990-569828	A2	19900820	<--	
US 1991-716899	B2	19910618	<--	
US 1991-717084	A2	19910618	<--	
US 1993-76239	A2	19930611	<--	
US 1993-76250	A2	19930611	<--	
US 1993-159674	B2	19931130	<--	
US 1993-159687	A2	19931130	<--	
US 1993-160232	A2	19931130	<--	
US 1994-307305	A2	19940916	<--	
WO 1990-US7500	W	19901219	<--	
US 1991-716793	A	19910618	<--	
US 1991-750877	A3	19910826	<--	
US 1992-818069	A3	19920108	<--	
WO 1992-US2615	A	19920331	<--	
US 1992-967974	A3	19921027	<--	
US 1993-17683	A3	19930212	<--	
US 1993-18112	B3	19930217	<--	
US 1993-85608	A3	19930630	<--	
US 1993-88268	A3	19930707	<--	
US 1993-163039	A3	19931206	<--	
US 1994-212553	B2	19940311	<--	
AU 1994-70416	A3	19940519	<--	
US 1994-346426	A	19941129	<--	
AU 1995-21850	A3	19941130	<--	
WO 1994-US13817	W	19941130	<--	
US 1995-395683	A3	19950228	<--	
US 1995-468056	A3	19950606	<--	
US 1995-471250	A3	19950606	<--	
US 1996-640554	B2	19960501	<--	
US 1996-665719	A3	19960618	<--	
US 1997-785661	B2	19970117	<--	

RE.CNT 314 THERE ARE 314 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT